Table 1 Overview of linagliptin clinical trials included in the CV safety analysis of adjudicated events
Study number | Treatment | Patients | Background | Follow-up (weeks) | Reference/NCT number |
|---|---|---|---|---|---|
1218.15 | Linagliptin 5Â mg Placebo; | 259 130 | Pioglitazone | 24 | Gomis et al. [39]. NCT00641043 |
1218.16 | Linagliptin 5Â mg Placebo; | 336 167 | None | 24 | Del Prato et al. [40]. NCT00621140 |
1218.17 | Linagliptin 5Â mg Placebo; | 523 177 | Metformin | 24 | Taskinen et al. [41]. NCT00601250 |
1218.18 | Linagliptin 5 mg Placebo; | 792 263 | Metformin + sulfonylurea | 24 | Owens et al. [42]. NCT00602472 |
1218.20 | Linagliptin 5 mg Glimepiride 1–4 mg; | 776 775 | Metformin | 104 | NCT00622284 |
1218.23 | Linagliptin 5Â mg Linagliptin 10Â mg Voglibose 0.6Â mg Placebo; | 159 160 162 80 | None | 26 | NCT00654381 |
1218.35 | Linagliptin 5Â mg Placebo; | 157 81 | Sulfonylurea | 18 | NCT00819091 |
1218.36* | Linagliptin 5 mg Placebo; | 628 627 | Basal insulin | ≥52 | NCT00954447 |
1218.43 | Linagliptin 5Â mg Placebo; | 67 63 | None | 52 | NCT00800683 |
1218.46 | Linagliptin 5Â mg Placebo; | 428 363 | Metformin | 24 | NCT00798161 |
1218.50 | Linagliptin 5Â mg Placebo; | 151 76 | None | 52 | NCT00740051 |
1218.52†| Linagliptin 5 mg Placebo; | 396 170 | Metformin | 54 | NCT00915772 |
1218.61* | Linagliptin 5 mg Placebo; | 183 89 | Metformin + pioglitazone | 24 | NCT00996658 |
1218.62* | Linagliptin 5Â mg Placebo; | 447 44 | Metformin | 12 | NCT01012037 |
1218.63* | Linagliptin 5Â mg Placebo; | 162 79 | None | 24 | NCT01084005 |
1218.64* | Linagliptin 5Â mg Placebo; | 113 122 | None | 52 | NCT01087502 |
1218.65* | Linagliptin 5Â mg Placebo; | 205 100 | Metformin | 24 | NCT01215097 |
1218.66* | Linagliptin 5Â mg Placebo; | 200 99 | None | 24 | NCT01214239 |
1218.75* | Linagliptin 5Â mg Placebo; | 101 115 | None | 24 | NCT01194830 |